File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Neuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review

TitleNeuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review
Authors
Issue Date2018
PublisherAdis International Ltd. The Journal's web site is located at http://www.springer.com/adis/journal/40264
Citation
Drug Safety, 2018, v. 41 n. 3, p. 253-265 How to Cite?
AbstractIntroduction: Leukotriene-modifying agents (LTMAs) including montelukast, zafirlukast, and zileuton are approved by the US Food and Drug Administration (FDA) for the treatment of asthma and allergic rhinitis. Various neuropsychiatric events (NEs) have been reported; however, the evidence of the association is conflicting. This systematic review investigates the association between NEs and LTMAs by assessing the relevant published literature. Methods: PubMed, EMBASE, MEDLINE, and Cochrane Library were searched using keywords. Studies designed to investigate the association were eligible for inclusion without restriction to any study design or language. The primary outcome was defined as suicidal conditions, while secondary outcomes included all other NEs. Results: Thirty-three studies were included for a narrative review. Four observational studies did not find a significant association, while ten pharmacovigilance studies using different global databases detected the signals. Notably, some studies suggest that the FDA warning issued in 2008 might have influenced the reporting rate of NEs as a result of increased awareness. Limitations: The risk of NEs was not quantified, because of the lack of randomized controlled trials and observational studies investigating the association. Conclusion: Many pharmacovigilance studies have been conducted to determine the association between NEs and LTMAs, but there is limited evidence from observational studies. High-quality epidemiological studies should be conducted to evaluate the association and quantify the risk, not only in children, but also in adults. © 2017, Springer International Publishing AG.
Persistent Identifierhttp://hdl.handle.net/10722/250019
ISSN
2019 Impact Factor: 3.442
2015 SCImago Journal Rankings: 1.359
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLaw, WY-
dc.contributor.authorWong, YS-
dc.contributor.authorAnand, S-
dc.contributor.authorWong, ICK-
dc.contributor.authorChan, EW-
dc.date.accessioned2017-12-20T09:19:29Z-
dc.date.available2017-12-20T09:19:29Z-
dc.date.issued2018-
dc.identifier.citationDrug Safety, 2018, v. 41 n. 3, p. 253-265-
dc.identifier.issn0114-5916-
dc.identifier.urihttp://hdl.handle.net/10722/250019-
dc.description.abstractIntroduction: Leukotriene-modifying agents (LTMAs) including montelukast, zafirlukast, and zileuton are approved by the US Food and Drug Administration (FDA) for the treatment of asthma and allergic rhinitis. Various neuropsychiatric events (NEs) have been reported; however, the evidence of the association is conflicting. This systematic review investigates the association between NEs and LTMAs by assessing the relevant published literature. Methods: PubMed, EMBASE, MEDLINE, and Cochrane Library were searched using keywords. Studies designed to investigate the association were eligible for inclusion without restriction to any study design or language. The primary outcome was defined as suicidal conditions, while secondary outcomes included all other NEs. Results: Thirty-three studies were included for a narrative review. Four observational studies did not find a significant association, while ten pharmacovigilance studies using different global databases detected the signals. Notably, some studies suggest that the FDA warning issued in 2008 might have influenced the reporting rate of NEs as a result of increased awareness. Limitations: The risk of NEs was not quantified, because of the lack of randomized controlled trials and observational studies investigating the association. Conclusion: Many pharmacovigilance studies have been conducted to determine the association between NEs and LTMAs, but there is limited evidence from observational studies. High-quality epidemiological studies should be conducted to evaluate the association and quantify the risk, not only in children, but also in adults. © 2017, Springer International Publishing AG.-
dc.languageeng-
dc.publisherAdis International Ltd. The Journal's web site is located at http://www.springer.com/adis/journal/40264-
dc.relation.ispartofDrug Safety-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/[insert DOI]-
dc.titleNeuropsychiatric Events Associated with Leukotriene-Modifying Agents: A Systematic Review-
dc.typeArticle-
dc.identifier.emailLaw, WY: swylaw@hku.hk-
dc.identifier.emailWong, YS: angelwys@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityChan, EW=rp01587-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s40264-017-0607-1-
dc.identifier.pmid29076063-
dc.identifier.scopuseid_2-s2.0-85032362746-
dc.identifier.hkuros283493-
dc.identifier.volume41-
dc.identifier.issue3-
dc.identifier.spage253-
dc.identifier.epage265-
dc.identifier.isiWOS:000426076900002-
dc.publisher.placeNew Zealand-
dc.identifier.issnl0114-5916-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats